UC Davis School of Veterinary Medicine

Pawlicy Advisor Appoints Chief Medical Officer, Surpassing 500k Personalized Recommendations for Pet Owners as Pet Insurance Gains Traction

Retrieved on: 
Thursday, July 6, 2023
Insurance, Learning, Emergency, Education, Veterinarian, Dog, Parent, Rise, Affenpinscher, ASPCA, Game Industry Report Magazine, American Animal Hospital Association, General practice, Animal, UC, UC Davis School of Veterinary Medicine, Pet, Cat, Veterinary medicine, DVM, Walther, Pet industry

NEW YORK, July 6, 2023 /PRNewswire/ -- Pawlicy Advisor, the leading, independent pet insurance marketplace recommended by the American Animal Hospital Association, today announced the appointment of a new Chief Medical Officer, on the heels of surpassing 500,000 pet owners who have been supported with personalized insurance recommendations. Pawlicy Advisor is committed to simplifying the process and aiding veterinary practices in educating pet owners through personalized assessments comparing top insurance companies – helping pet owners better understand insurance offerings and what options are right for them based on breed-specific health risks, the expected lifetime costs, location, personal preferences, and more.

Key Points: 
  • In providing personalized insurance advice to over half a million pet owners, Pawlicy Advisor has gained a unique understanding of owners and veterinary practices across the country, learning more about why pet owners choose insurance, the most common pet medical needs and the impact insurance has on the care vets can provide in the long-term.
  • Walther's veterinary background has allowed him to see firsthand the positive financial and medical impact pet insurance can provide pet parents and veterinarians.
  • Pawlicy Advisor data shows 56% of pet owners are looking for pet insurance for young animals – in comparison to 10% of pets that are older.
  • Pet Insurance Market is on the Rise, Improving Vet Quality of Life
    Pawlicy Advisor's feedback from pet owners has been overwhelmingly positive as they navigate the pet insurance landscape.

PetSmart Charities to Name Endowed Chair at UC Davis School of Veterinary Medicine with $6 Million Gift

Retrieved on: 
Thursday, May 25, 2023
UAF, PetSmart Charities, UC Davis School of Veterinary Medicine, University of California, Davis, Partnership, University, CSU, Yukon–Kuskokwim Delta, Veterinarian, Colorado State University, Curriculum, Molina Healthcare, Public, Research, University college, Language, Student, University of Alaska Fairbanks, Animal, UC, School, Pet, PetSmart, Faculty, Charitable organization, Health, Veterinary medicine, Nursing, Management

PHOENIX, May 25, 2023 /PRNewswire/ -- PetSmart Charities® will name an endowed chair at the University of California, Davis, School of Veterinary Medicine for $6 million. The landmark partnership marks the largest gift to date made by the top funder of animal welfare in the U.S. to bolster the commitment to improving access to veterinary care.

Key Points: 
  • PHOENIX, May 25, 2023 /PRNewswire/ -- PetSmart Charities ® will name an endowed chair at the University of California, Davis, School of Veterinary Medicine for $6 million.
  • According to research commissioned by PetSmart Charities, in the U.S., 50 million pets a year lack access to standard veterinary care.
  • In 2023, PetSmart Charities committed $100 million over the next five years to address geographic, language and financial barriers to veterinary care.
  • UC Davis' School of Veterinary Medicine was chosen to receive the gift for its sustained priority of improving access to veterinary care and integrated approach to student training.

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

Retrieved on: 
Thursday, February 23, 2023
Biomarker, Principal investigator, Safety, University, CIRM, Mayo Clinic, Gerontology, Physiology, Research, OA, Patient, Arthralgia, UC Davis School of Veterinary Medicine, Inflammation, Ageing, California Institute for Regenerative Medicine, NIH, Osteoarthritis, Disability, AAV, HIV disease progression rates, PALO, Clinical professor, Women's health, University of Leeds, DSM-IV codes, Regenerative medicine, Pharmaceutical industry, Health, Rheumatology, Orthopedic surgery

The funding will be used to support Genascence's Phase 1b clinical trial of GNSC-001 in knee osteoarthritis (OA), as well as phase-appropriate manufacturing activities.

Key Points: 
  • The funding will be used to support Genascence's Phase 1b clinical trial of GNSC-001 in knee osteoarthritis (OA), as well as phase-appropriate manufacturing activities.
  • "We applaud the Genascence team for tackling one of the most prevalent degenerative diseases.
  • The Phase 1b clinical trial entitled, "A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study Evaluating GNSC-001 Safety, Pharmacodynamics, and Biomarkers in Knee Osteoarthritis," is designed to enroll 50 patients with OA.
  • "We are honored to have CIRM award this funding to help advance GNSC-001, our lead clinical program in OA where we hope to demonstrate transformative results for patients."

WeatherTech Celebrates a Decade on the Super Bowl With Their Signature Message

Retrieved on: 
Tuesday, February 7, 2023
WeatherTech, Element, Veterinary medicine, Kansas City Chiefs, State Farm Stadium, University of Wisconsin–Madison, Advertising, Engineering, University, American Dream, Bowl game, Research, Super Bowl, Philadelphia Eagles, Growth, FOX, School, UC Davis School of Veterinary Medicine, Pet, Soil, Cancer, Television, Scout

BOLINGBROOK, Ill., Feb. 7, 2023 /PRNewswire-PRWeb/ -- WeatherTech, the leading manufacturer of premium American-made automotive accessories, home and pet care products, will air a new 30-second commercial "We All Win" during the FOX broadcast of Super Bowl LVII, February 12, 2023.

Key Points: 
  • This year marks the 10th anniversary of WeatherTech's first time as an advertiser in the Super Bowl.
  • This year marks the 10th anniversary of WeatherTech being a first-time advertiser on the Super Bowl.
  • Thus, "YOU CAN'T DO THAT" became the theme of WeatherTech's first Super Bowl commercial.
  • Before he passed due to cancer, Scout appeared in many WeatherTech commercials over the years, including a starring role in several of their Super Bowl spots.

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022
Diagnosis, Mouse, Fever, Blister, Patient, School, Biotechnology, Nerve agent, Fissure, Severe cognitive impairment, UC Davis School of Veterinary Medicine, Disease, Louisiana State University, Chills, Erythema, Infection, Company, National, LSU, Simplex, Ulcer, Veterinary medicine, Virology, Guinea, NIH, World, WHO, Western world, Genital herpes, World Health Organization, Myalgia, Virus, Human, Animal, Neonatal infection, Vaccine, Foundation for the National Institutes of Health, HSV-2, HSV, Pharmaceutical industry

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.

LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections

Retrieved on: 
Tuesday, July 5, 2022
University of California, Davis, TSX Venture Exchange, SEDAR, Urinary tract infection, Intention, UC, OTCQB, School, UC Davis School of Veterinary Medicine, Journal of Veterinary Internal Medicine, Food safety, University, GLOBE, Infection, Innovation and Entrepreneurship Group, Company, Entrepreneurship, Genetic testing, Veterinary medicine, Innovation, MBA, SVM, ID, Technology, Doctor of Philosophy, LXG, Dog, Executive, PCR, American College, Cat, News, Veterinarian, DVM

This webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies.

Key Points: 
  • This webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies.
  • Dr. Sykes is a Professor of Small Animal Internal Medicine (Infectious Diseases) and the Executive Director of Innovation and Entrepreneurship in the School of Veterinary Medicine (SVM) at UC Davis.
  • The MiQLab system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Intoleran Overcomes Food Intolerances

Retrieved on: 
Tuesday, May 24, 2022
Human, UC, Food intolerance, Medicine, Digestion, Enzyme, Family, Food, Goal, Health, Intolerance, UC Davis School of Medicine, Brain, Time, Nutrient, Diet, Galactose, UC Davis School of Veterinary Medicine, CDC, Immune system, Friends, Fructose, Fructan, Sucrose, Lactose, Sugar, Feed manufacturing, Dairy product, Dietary supplement

FORT LAUDERDALE, Fla., May 24, 2022 /PRNewswire/ -- The staff at the health brand Intoleran is well aware of the struggle that many Americans face when it comes to gut health. The CDC reports that millions of Americans end up visiting the emergency department each year due to their digestive troubles. At the same time, others, like UC Davis School of medicine, have found that a healthy gut impacts far-reaching areas of the body, like the immune system and the brain.

Key Points: 
  • "We are specialists with the best supplements for food intolerances to help release you from your digestive issues," explains company owner Harmen Treep, "if you suffer from a food intolerance, our supplements can quickly and easily help you digest troublesome foods."
  • About Intoleran: Intoleran was founded in the Netherlands in 2008.
  • These address a variety of food intolerances, including lactose, fructose, fructans, galactans, and sucrose.
  • Intoleran products assist the digestive system by helping to properly digest food and, consequently, avoiding many of the unpleasant side effects that come from food intolerances.

Rational Vaccines' Herpes Vaccine RVx1001 Shows Promise as a Viral Vector Platform to Express Malaria Proteins and Confer Protection against Malaria Infection in Mice According to a Recent Study Published in Vaccines

Retrieved on: 
Tuesday, May 10, 2022
School, Herpes simplex virus, State Research Center of Virology and Biotechnology VECTOR, Simplex, Mortality, Parasitism, Mouse, Biological life cycle, Company, Travel, Veterinary medicine, Red blood cell, Liver stage antigens, Safety, WHO, Infection, Louisiana State University, Human, Diagnosis, Incidence, Plasmodium falciparum, List of life sciences, Death, Cancer, Disease, UC Davis School of Veterinary Medicine, Guinea, SCID, Liver, LSU, Protein, HSV, Plasmodium yoelii, Risk, Multimedia, Vaccine, Research, Biotechnology, Virology, DRS, Vaccine, Malaria, Plasmodium

WOBURN, Mass. and OXFORD, England, May 10, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced that the Company's attenuated herpes simplex virus type-1 (HSV-1)-vaccine RVx1001 can be utilized as a viral vaccine vector to protect against malaria infections.

Key Points: 
  • Research shows company's novel HSV-1-derived viral vaccine has significant potential to produce vaccines to combat infectious diseases including malaria.
  • The study, "An Attenuated HSV-1 Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection Against Infectious Sporozoite Challenge," was published in Vaccines and can be accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875294/
    The published study reported on the development of a highly efficacious trivalent malaria vaccine using the Rational Vaccines RVx1001 vaccine as a vector.
  • The construction of the HSV-1 vectored vaccine expressed three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3, and TMP21) as fusion proteins with the VP26 viral capsid protein.
  • "These data show that the Rational Vaccines HSV-1 vaccine can be effectively utilized as a vector platform to protect against malaria and other infectious diseases.

Petco Love Announces $1 Million in New Investments to Fight Pet Cancer

Retrieved on: 
Tuesday, May 3, 2022
PETS, BLUE, Parent, School, University, Bishop, Lead, DVM, Instagram, Twitter, Dog, Cat, Death, Veterinary medicine, University Foundation, Love, Patient, Texas A&M University, Partnership, Petco, Organization, Louisiana State University, University of Pennsylvania, Family, Cancer, Human, Food, Industry, Virginia Tech Foundation, Pet, Airedale, Adoption, Poultry, LinkedIn, 2006 Hezbollah cross-border raid, UC Davis School of Veterinary Medicine, NO, Animal nutritionist, LSU, Research, SAN, Growth, Awareness, Veterinarian, Multimedia, Bottled water, Medical imaging, Facebook

SAN ANTONIO, May 3, 2022 /PRNewswire/ -- Today the national nonprofit organization Petco Love announced its commitment to continue fighting against the number one disease-related cause of death for dogs and cats in the U.S.: pet cancer, which afflicts one in four dogs and one in five cats.

Key Points: 
  • Petco Love has invested $18M to date in subsidized pet cancer care and research to improve treatments.
  • In partnership with Blue Buffalo, this May marks Petco Love's 13th annual pet cancer campaign, furthering its ongoing cause as a champion of pets and the people who love them.
  • Our goal is to make treatment accessible to more pets and their pet parents by supporting subsidized care options and research for better treatments," said Susanne Kogut, president of Petco Love.
  • Throughout May, Blue Buffalo and Petco Love will drive awareness of the pervasiveness of pet cancer, the need for early detection , and how pet parents can find support and/or help others in need.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.